Instil Bio Inc
TIL
Get informed when a big investor buys or sells
+ FollowMarket Cap$54.73M
Close$
$1.00
87.9% downside
Current Fair Value
87.9% downsideOvervalued by 87.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $54.73 Million |
|---|---|
| Enterprise Value | $49.71 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-10.7 |
| Beta | 1.95 |
| Outstanding Shares | 6,781,976 |
Return
| Return on Equity | -42.80% |
|---|---|
| Return on Assets | -23.64% |
| Return on Invested Capital | -26.39% |
Valuation & Multiples
| P/E Ratio | -1.16 |
|---|---|
| PEG | 1.36 |
| Price to Sales | - |
| Price to Book Ratio | 0.51 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.96 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.62
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 7, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 33.24%▼ 4.40% |
|---|---|
| Total Invested | $18.58M▼ 33.61% |
| Investors Holding | 31▲ 3.00% |
ESG Score
No data
About Instil Bio Inc
150 employeesInstil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer.